Episode Details

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Identify areas of unmet need in KRAS-mutant NSCLC across diverse KRAS variants in pretreated advanced settings; Describe the rationale for the use of RAS(ON) inhibitors for patients with KRAS-mutated NSCLC, based on evidence; and Assess how RAS(ON) inhibitors may be optimally used in clinical practice as they become available.